Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation

Clinical Infectious Diseases

Volumn 57, Issue 10, 2013, Pages 1483-1488

  Grant, Philip M ^a   Kitch, Douglas ^b   McComsey, Grace A ^c   Dube, Michael P ^d   Haubrich, Richard ^e   Huang, Jeannie ^e   Riddler, Sharon ^f   Tebas, Pablo ^g   Zolopa, Andrew R ^a   Collier, Ann C ^h   Brown, Todd T ⁱ  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Administration and dosage; Anti HIV agents; Bone density; Drug therapy virology; HIV infections

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; WHOLE BODY IMAGING;

ADMINISTRATION AND DOSAGE; ANTI-HIV AGENTS; BONE DENSITY; DRUG THERAPY/VIROLOGY; HIV INFECTIONS;

ABSORPTIOMETRY, PHOTON; ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; RISK FACTORS; VIRAL LOAD;

EID: 84887987230     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit538     Document Type: Article

References (27)

1. Weber R, Smith C, D: A: D Study Group. Trends over time in underlying causes of death in the D: A: D study from 1999 to 2011. In: International AIDS Conference, Washington, DC, 22-27 July 2012. Abstract THAB0304.
2. Grund B, Pen G, Gibert C.L., et al Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23: 1519-29.
3. Brown TT, Qaqish RB Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-74.
4. Womack JA, Goulet JL, Gibert C, et al Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PloS One 2011; 6: e17217.
5. McComsey GA, Kitch D, Daar E.S., et al Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-801.
6. Reynes J, Trinh R, Pulido F., et al Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS Study. AIDS Res Hum Retroviruses 2013; 29: 256-65.
7. Ofotokun I, McIntosh E, Weitzmann MN HIV: inflammation and bone. Curr HIV/AIDS Rep 2012; 9: 16-25.
8. Dube MP, Parker RA, Tebas P, et al Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-18.
9. Haubrich RH, Riddler SA, DiRienzo A.G., et al Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-18.
10. Huang J, Hughes M, Riddler S., Haubrich R; AIDS Clinical Trials Group 5142 Study Team. Effects of randomized regimen and nucleoside reverse transcriptase inhibitor (NRTI) selection on 96 week bone mineral density (BMD): results from ACTG 5142. In: XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. Abstract WEAB0304.
11. Shafer RW, Smeaton LM, Robbins G.K., et al Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2304-15.
12. Riddler SA, Haubrich R, DiRienzo A.G., et al Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
13. Daar ES, Tierney C, Fischl M.A., et al Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
14. Cummings SR, Black DM, Nevitt M.C., et al Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-5.
15. Tsai KS, Chieng PU, Huang K.M., Su CT, Lee TK Predictive value of total body bone mineral density for vertebral fractures in elderly women. Geriatric Study Group. J Formos Med Assoc 1992; 91: 873-8.
16. Nolan D, Upton R, McKinnon E., et al Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15: 1275-80.
17. Jacobson DL, Spiegelman D, Knox T.K., Wilson IB Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49: 298-308.
18. Brown TT, McComsey GA, King M.S., Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51: 554-61.
19. Bedi B, Li JY, Grassi F, Tawfeek H., Weitzmann MN, Pacifici R. Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss. Ann N Y Acad Sci 2010; 1192: 215-21.
20. Cenci S, Weitzmann MN, Roggia C, et al Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106: 1229-37.
21. Gao Y, Wu X, Terauchi M., et al T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab 2008; 8: 132-45.
22. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22: 395-402.
23. Erlandson KM, Allshouse AA, Jankowski C.M., et al Risk factors for falls in HIV-infected persons. J Acquir immune Defic Syndr 2012; 61: 484-9.
24. Gallant JE, Staszewski S, Pozniak A.L., et al Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
25. Bedimo R, Maalouf NM, Zhang S, Drechsler H., Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26: 825-31.
26. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002; 13: 105-12.
27. Yin MT, Kendall MA, Wu X, et al Fractures after antiretroviral initiation. AIDS 2012; 26: 2175-84.